efrapeptin G

peptaibiotic produced by an atypical strain of Acremonium sp., cultured from a marine sponge collected in Papua New Guinea; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Boot, Claudia M: 2 articles (09/2007 - 01/2006)
2.	Crews, Phillip: 2 articles (09/2007 - 01/2006)
3.	Tenney, Karen: 2 articles (09/2007 - 01/2006)
4.	Valeriote, Frederick A: 2 articles (09/2007 - 01/2006)
5.	Amagata, Taro: 1 article (09/2007)
6.	Compton, Jennifer E: 1 article (09/2007)
7.	Pietraszkiewicz, Halina: 1 article (09/2007)

Related Diseases

1.

Neoplasms (Cancer) 01/01/2006 - "Efrapeptin G (3) displayed potent cytotoxicity against murine cancer cell lines, while RHM1 (1) and RHM2 (2) showed weak cytotoxicity against murine cancer cell lines; efrapeptin G (3) and RHM1 (1) also demonstrated antibacterial activity." 09/24/2007 - "An initial therapeutic assessment suggested a continuous (168 h) exposure of at least 2 ng/ml, or a daily (24 h) exposure of at least 300 ng/ml for H125 cells treated with efrapeptin G, and a continuous (168 h) exposure of at least 190 ng/ml for HCT-116 cells treated with destruxin E2 chlorohydrin, will cause 90% tumor cell death in vitro."

Related Drugs and Biologics

1.	destruxin E2 chlorohydrin